



950 Tower Lane
Suite 1050
Foster City, CA 94404
650-667-4085
www.mirumpharma.com

October 28th, 2021

To Whom It May Concern:

This email is to inform the Attorney General's Office for the State of Vermont that Mirum Pharmaceuticals has launched a new reportable product and therefore to meet the requirements of 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs). LIVMARLI™ is a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. Please see the below information to comply with Vermont's submission requirements.

- The product was granted a breakthrough therapy designation
- The product was a priority review by the FDA.
- Information pertaining to marketing and pricing plans is not currently publicly available.
- The volume of patients is not currently publicly available.

Please contact us with any questions.

Best,

Jeffrey K. Murtha PharmD, R.Ph
Sr. Director, US Payer Lead
215-206-8386
Jeff.murtha@mirumpharma.com